A new Inserm Transfert Technology Offers experience coming soon in April !


Novel target and mAb candidates for the treatment of HCMV infection

The present invention relates to a method for treating an infection, particularly HCMV infection. To date, there are very few reports on the role of DC-SIGN+ dendritic cells in very early phases of viral infections. By using four anti-human DC-SIGN monoclonal antibodies, the inventors have demonstrated that DC-SIGN might be considered as the most important receptor for both pre- and post-fusion HCMV gB on monocyte-derived dendritic cells (MDDCs). In particular, the invention relates to a method for treating an infection in a subject in need thereof comprising a step of administering to said subject an agent that blocks the interaction between DC-SIGN and an infectious ligand.

Keywords : Infectious Diseases, Antivirals, HCMV, DC-SIGN
Patent Application number : EP17305064.2
Patent Application date : 23-01-2017
Multidisciplinary field : -
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : -
Inventors : Jean-Jacques PIN
Publications :
  • Org Biomol Chem. 2017 Sep 20;15(36):7660-7671. doi: 10.1039/c7ob01569k.

Related offers

The 10 Last viewed

You haven't seen any form yet.